Nivolumab no tratamento de pacientes com câncer cervical persistente, recorrente ou metastático
Uma avaliação de fase II de nivolumab, um anticorpo totalmente humano contra PD-1, no tratamento de câncer cervical persistente ou recorrente
This phase II trial studies the side effects and how well nivolumab works in treating patients with cervical cancer that has grown, come back, or spread to other places in the body. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
PRIMARY OBJECTIVES:
I. To assess the antitumor activity (proportion of objective response by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) of nivolumab with objective tumor response in patients with persistent, recurrent or metastatic carcinoma of the cervix.
II. To determine the nature and degree of toxicity of nivolumab as assessed by Common Terminology Criteria for Adverse Events (CTCAE) in patients with persistent, recurrent or metastatic carcinoma of the cervix.
SECONDARY OBJECTIVES:
I. To estimate the duration of progression-free survival (PFS) and overall survival (OS).
TERTIARY OBJECTIVES:
I. To systematically evaluate programmed cell death (PD)-1 and B7 homolog 1 (B7-H1) (i.e., PD-1 ligand) expression in tumor infiltrating lymphocytes (TILs) and cervical cancer cells and explore their correlations with objective response, PFS, and OS in nivolumab-treated patients with PD-1 and B7-H1 scoring results.
II. To explore the composition of immune infiltrates in tumor specimens/biopsies from primary and/or metastatic/recurrent sites with selected markers including (but not limited) to cluster of differentiation (CD)4+, CD8+, forkhead box P3 (FoxP3), CD25, lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin mucin-3 (TIM-3), and inducible T-cell co-stimulator (ICOS) and their correlations to objective response, PFS and OS in nivolumab-treated patients.
III. To evaluate human papillomavirus (HPV) status and to explore the changes of pre- and post-immune therapy responses to HPV16/18/31/35/45 E7 antigens in patients peripheral blood lymphocytes (PBL) and serum using proliferative and interferon (IFN)-gamma enzyme-linked immunospot (ELISPOT) (cellular immunity) and serological (enzyme-linked immunosorbent assay [ELISA]) assays.
IV. To explore the levels of circulating tumor cells (CTCs) pre-treatment and at 8 and 12 weeks and their association with patient outcome.
OUTLINE:
Patients receive nivolumab intravenously (IV) over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 98508
- Anchorage Associates in Radiation Medicine
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Breast Care and Surgery LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Oncology and Hematology LLC
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Women's Cancer Care
-
Anchorage, Alaska, Estados Unidos, 99508
- Anchorage Oncology Centre
-
Anchorage, Alaska, Estados Unidos, 99508
- Katmai Oncology Group
-
Anchorage, Alaska, Estados Unidos, 99508
- Providence Alaska Medical Center
-
Anchorage, Alaska, Estados Unidos, 99504
- Anchorage Radiation Therapy Center
-
Anchorage, Alaska, Estados Unidos, 99508
- Alaska Regional Hospital
-
-
Arkansas
-
Hot Springs, Arkansas, Estados Unidos, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
-
California
-
Auburn, California, Estados Unidos, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Estados Unidos, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Baldwin Park, California, Estados Unidos, 91706
- Kaiser Permanente-Baldwin Park
-
Berkeley, California, Estados Unidos, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Burbank, California, Estados Unidos, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Burlingame, California, Estados Unidos, 94010
- Mills-Peninsula Medical Center
-
Cameron Park, California, Estados Unidos, 95682
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Castro Valley, California, Estados Unidos, 94546
- Eden Hospital Medical Center
-
Davis, California, Estados Unidos, 95616
- Sutter Davis Hospital
-
La Jolla, California, Estados Unidos, 92093
- UC San Diego Moores Cancer Center
-
Modesto, California, Estados Unidos, 95355
- Memorial Medical Center
-
Mountain View, California, Estados Unidos, 94040
- Palo Alto Medical Foundation-Camino Division
-
Mountain View, California, Estados Unidos, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
Palo Alto, California, Estados Unidos, 94301
- Palo Alto Medical Foundation Health Care
-
Roseville, California, Estados Unidos, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Estados Unidos, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Estados Unidos, 95816
- Sutter Medical Center Sacramento
-
San Diego, California, Estados Unidos, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, Estados Unidos, 92108
- Kaiser Permanente-Rio San Diego
-
San Francisco, California, Estados Unidos, 94115
- California Pacific Medical Center-Pacific Campus
-
San Marcos, California, Estados Unidos, 92078
- Kaiser Permanente-San Marcos
-
Santa Cruz, California, Estados Unidos, 95065
- Palo Alto Medical Foundation-Santa Cruz
-
Santa Rosa, California, Estados Unidos, 95403
- Sutter Pacific Medical Foundation
-
Sunnyvale, California, Estados Unidos, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Vallejo, California, Estados Unidos, 94589
- Sutter Solano Medical Center/Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University
-
-
Delaware
-
Lewes, Delaware, Estados Unidos, 19958
- Beebe Medical Center
-
Newark, Delaware, Estados Unidos, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Estados Unidos, 19713
- Delaware Clinical and Laboratory Physicians PA
-
Newark, Delaware, Estados Unidos, 19713
- Medical Oncology Hematology Consultants PA
-
Newark, Delaware, Estados Unidos, 19718
- Christiana Care Health System-Christiana Hospital
-
Rehoboth Beach, Delaware, Estados Unidos, 19971
- Beebe Health Campus
-
Seaford, Delaware, Estados Unidos, 19973
- TidalHealth Nanticoke / Allen Cancer Center
-
Wilmington, Delaware, Estados Unidos, 19801
- Christiana Care Health System-Wilmington Hospital
-
-
Georgia
-
Savannah, Georgia, Estados Unidos, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
Savannah, Georgia, Estados Unidos, 31404
- Memorial Health University Medical Center
-
Savannah, Georgia, Estados Unidos, 31404
- Summit Cancer Care-Memorial
-
Savannah, Georgia, Estados Unidos, 31404
- Low Country Cancer Care
-
-
Idaho
-
Boise, Idaho, Estados Unidos, 83712
- Saint Luke's Cancer Institute - Boise
-
Coeur d'Alene, Idaho, Estados Unidos, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, Estados Unidos, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Estados Unidos, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Estados Unidos, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, Estados Unidos, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, Estados Unidos, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, Estados Unidos, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, Estados Unidos, 61704
- Illinois CancerCare-Bloomington
-
Bloomington, Illinois, Estados Unidos, 61701
- OSF Saint Joseph Medical Center
-
Canton, Illinois, Estados Unidos, 61520
- Illinois CancerCare-Canton
-
Carbondale, Illinois, Estados Unidos, 62902
- Memorial Hospital of Carbondale
-
Carthage, Illinois, Estados Unidos, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, Estados Unidos, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
Decatur, Illinois, Estados Unidos, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, Estados Unidos, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, Estados Unidos, 62401
- Crossroads Cancer Center
-
Eureka, Illinois, Estados Unidos, 61530
- Illinois CancerCare-Eureka
-
Galesburg, Illinois, Estados Unidos, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Estados Unidos, 61401
- Illinois CancerCare-Galesburg
-
Hinsdale, Illinois, Estados Unidos, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
Kewanee, Illinois, Estados Unidos, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, Estados Unidos, 61455
- Illinois CancerCare-Macomb
-
Mount Vernon, Illinois, Estados Unidos, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, Estados Unidos, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, Estados Unidos, 61350
- Illinois CancerCare-Ottawa Clinic
-
Ottawa, Illinois, Estados Unidos, 61350
- Radiation Oncology of Northern Illinois
-
Pekin, Illinois, Estados Unidos, 61554
- Illinois CancerCare-Pekin
-
Pekin, Illinois, Estados Unidos, 61554
- OSF Saint Francis Radiation Oncology at Pekin
-
Peoria, Illinois, Estados Unidos, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Estados Unidos, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Estados Unidos, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, Estados Unidos, 61615
- OSF Saint Francis Radiation Oncology at Peoria Cancer Center
-
Peru, Illinois, Estados Unidos, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Estados Unidos, 61354
- Valley Radiation Oncology
-
Princeton, Illinois, Estados Unidos, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Estados Unidos, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield Clinic
-
Springfield, Illinois, Estados Unidos, 62702
- Central Illinois Hematology Oncology Center
-
Springfield, Illinois, Estados Unidos, 62781
- Springfield Memorial Hospital
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, Estados Unidos, 46202
- Sidney and Lois Eskenazi Hospital
-
Richmond, Indiana, Estados Unidos, 47374
- Reid Health
-
-
Iowa
-
Clive, Iowa, Estados Unidos, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Estados Unidos, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Estados Unidos, 51503
- Alegent Health Mercy Hospital
-
Creston, Iowa, Estados Unidos, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Estados Unidos, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Estados Unidos, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Estados Unidos, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Estados Unidos, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Chanute, Kansas, Estados Unidos, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Estados Unidos, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Estados Unidos, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Estados Unidos, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Estados Unidos, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Estados Unidos, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Estados Unidos, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Estados Unidos, 67905
- Cancer Center of Kansas-Liberal
-
Newton, Kansas, Estados Unidos, 67114
- Cancer Center of Kansas - Newton
-
Parsons, Kansas, Estados Unidos, 67357
- Cancer Center of Kansas - Parsons
-
Pratt, Kansas, Estados Unidos, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Estados Unidos, 67401
- Cancer Center of Kansas - Salina
-
Wellington, Kansas, Estados Unidos, 67152
- Cancer Center of Kansas - Wellington
-
Wichita, Kansas, Estados Unidos, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Estados Unidos, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Estados Unidos, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Estados Unidos, 67208
- Associates In Womens Health
-
Winfield, Kansas, Estados Unidos, 67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Bardstown, Kentucky, Estados Unidos, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin, Kentucky, Estados Unidos, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Estados Unidos, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Estados Unidos, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Louisville, Kentucky, Estados Unidos, 40202
- Jewish Hospital
-
Louisville, Kentucky, Estados Unidos, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Estados Unidos, 40215
- Saints Mary and Elizabeth Hospital
-
Shepherdsville, Kentucky, Estados Unidos, 40165
- Jewish Hospital Medical Center South
-
-
Maine
-
Scarborough, Maine, Estados Unidos, 04074
- MaineHealth Maine Medical Center- Scarborough
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Estados Unidos, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital Cancer Center
-
Burlington, Massachusetts, Estados Unidos, 01805
- Lahey Clinic
-
-
Michigan
-
Brownstown, Michigan, Estados Unidos, 48183
- Henry Ford Cancer Institute-Downriver
-
Clinton Township, Michigan, Estados Unidos, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, Estados Unidos, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Estados Unidos, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Weisberg Cancer Treatment Center
-
Novi, Michigan, Estados Unidos, 48377
- Henry Ford Medical Center-Columbus
-
West Bloomfield, Michigan, Estados Unidos, 48322
- Henry Ford West Bloomfield Hospital
-
-
Missouri
-
Bolivar, Missouri, Estados Unidos, 65613
- Central Care Cancer Center - Bolivar
-
Bonne Terre, Missouri, Estados Unidos, 63628
- Parkland Health Center-Bonne Terre
-
Branson, Missouri, Estados Unidos, 65616
- Cox Cancer Center Branson
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Saint Francis Medical Center
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Mercy Cancer Center - Cape Girardeau
-
Jefferson City, Missouri, Estados Unidos, 65109
- MU Health Care Goldschmidt Cancer Center
-
Joplin, Missouri, Estados Unidos, 64804
- Freeman Health System
-
Joplin, Missouri, Estados Unidos, 64804
- Mercy Hospital Joplin
-
Rolla, Missouri, Estados Unidos, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Estados Unidos, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Estados Unidos, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Estados Unidos, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Estados Unidos, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Estados Unidos, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Estados Unidos, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Estados Unidos, 63141
- Mercy Hospital Saint Louis
-
Sullivan, Missouri, Estados Unidos, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Anaconda, Montana, Estados Unidos, 59711
- Community Hospital of Anaconda
-
Billings, Montana, Estados Unidos, 59101
- Billings Clinic Cancer Center
-
Billings, Montana, Estados Unidos, 59101
- Saint Vincent Healthcare
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Health Deaconess Hospital
-
Butte, Montana, Estados Unidos, 59701
- Saint James Community Hospital and Cancer Treatment Center
-
Great Falls, Montana, Estados Unidos, 59405
- Great Falls Clinic
-
Great Falls, Montana, Estados Unidos, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, Estados Unidos, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, Estados Unidos, 59901
- Logan Health Medical Center
-
Missoula, Montana, Estados Unidos, 59802
- Saint Patrick Hospital - Community Hospital
-
Missoula, Montana, Estados Unidos, 59804
- Community Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, Estados Unidos, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Estados Unidos, 68847
- CHI Health Good Samaritan
-
Kearney, Nebraska, Estados Unidos, 68845
- Fred and Pamela Buffett Cancer Center - Kearney
-
Lincoln, Nebraska, Estados Unidos, 68510
- Saint Elizabeth Regional Medical Center
-
Omaha, Nebraska, Estados Unidos, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Estados Unidos, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Estados Unidos, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Estados Unidos, 68122
- Hematology and Oncology Consultants PC
-
Papillion, Nebraska, Estados Unidos, 68046
- Midlands Community Hospital
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89106
- Women's Cancer Center of Nevada
-
-
New Jersey
-
Camden, New Jersey, Estados Unidos, 08103
- Cooper Hospital University Medical Center
-
Hackensack, New Jersey, Estados Unidos, 07601
- Hackensack University Medical Center
-
Voorhees Township, New Jersey, Estados Unidos, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Estados Unidos, 87106
- University of New Mexico Cancer Center
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Clinton, North Carolina, Estados Unidos, 28328
- Southeastern Medical Oncology Center-Clinton
-
Clinton, North Carolina, Estados Unidos, 28328
- Sampson Radiation Oncology
-
Goldsboro, North Carolina, Estados Unidos, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Goldsboro, North Carolina, Estados Unidos, 27534
- Wayne Memorial Hospital
-
Goldsboro, North Carolina, Estados Unidos, 27534
- Wayne Radiation Oncology
-
Jacksonville, North Carolina, Estados Unidos, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Jacksonville, North Carolina, Estados Unidos, 28546
- Onslow Memorial Hospital
-
-
Ohio
-
Beachwood, Ohio, Estados Unidos, 44122
- UHHS-Chagrin Highlands Medical Center
-
Belpre, Ohio, Estados Unidos, 45714
- Strecker Cancer Center-Belpre
-
Centerville, Ohio, Estados Unidos, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, Estados Unidos, 45459
- Dayton Physicians LLC-Miami Valley South
-
Chillicothe, Ohio, Estados Unidos, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, Estados Unidos, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Estados Unidos, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Estados Unidos, 45236
- Oncology Hematology Care Inc-Kenwood
-
Cincinnati, Ohio, Estados Unidos, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Estados Unidos, 45255
- TriHealth Cancer Institute-Anderson
-
Cleveland, Ohio, Estados Unidos, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Estados Unidos, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Estados Unidos, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Estados Unidos, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, Estados Unidos, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, Estados Unidos, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, Estados Unidos, 43228
- Doctors Hospital
-
Columbus, Ohio, Estados Unidos, 43213
- Mount Carmel East Hospital
-
Columbus, Ohio, Estados Unidos, 43215
- Grant Medical Center
-
Columbus, Ohio, Estados Unidos, 43222
- Mount Carmel Health Center West
-
Dayton, Ohio, Estados Unidos, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, Estados Unidos, 45409
- Miami Valley Hospital
-
Dayton, Ohio, Estados Unidos, 45415
- Miami Valley Hospital North
-
Dayton, Ohio, Estados Unidos, 45415
- Dayton Physician LLC - Englewood
-
Delaware, Ohio, Estados Unidos, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, Estados Unidos, 43015
- Delaware Radiation Oncology
-
Delaware, Ohio, Estados Unidos, 43015
- Grady Memorial Hospital
-
Findlay, Ohio, Estados Unidos, 45840
- Blanchard Valley Hospital
-
Findlay, Ohio, Estados Unidos, 45840
- Armes Family Cancer Center
-
Findlay, Ohio, Estados Unidos, 45840
- Orion Cancer Care
-
Franklin, Ohio, Estados Unidos, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Franklin, Ohio, Estados Unidos, 45005
- Dayton Physicians LLC-Atrium
-
Greenville, Ohio, Estados Unidos, 45331
- Wayne Hospital
-
Greenville, Ohio, Estados Unidos, 45331
- Dayton Physicians LLC-Wayne
-
Kettering, Ohio, Estados Unidos, 45429
- Kettering Medical Center
-
Kettering, Ohio, Estados Unidos, 45409
- Greater Dayton Cancer Center
-
Lancaster, Ohio, Estados Unidos, 43130
- Fairfield Medical Center
-
Marietta, Ohio, Estados Unidos, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, Estados Unidos, 43302
- OhioHealth Marion General Hospital
-
Mayfield Heights, Ohio, Estados Unidos, 44124
- Hillcrest Hospital Cancer Center
-
Mayfield Heights, Ohio, Estados Unidos, 44124
- UH Seidman Cancer Center at Landerbrook Health Center
-
Mentor, Ohio, Estados Unidos, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
Middletown, Ohio, Estados Unidos, 45042
- Dayton Physicians LLC-Signal Point
-
Mount Vernon, Ohio, Estados Unidos, 43050
- Knox Community Hospital
-
Newark, Ohio, Estados Unidos, 43055
- Licking Memorial Hospital
-
Newark, Ohio, Estados Unidos, 43055
- Newark Radiation Oncology
-
Portsmouth, Ohio, Estados Unidos, 45662
- Southern Ohio Medical Center
-
Sidney, Ohio, Estados Unidos, 45365
- Dayton Physicians LLC-Wilson
-
Springfield, Ohio, Estados Unidos, 45504
- Springfield Regional Cancer Center
-
Springfield, Ohio, Estados Unidos, 45504
- Springfield Regional Medical Center
-
Troy, Ohio, Estados Unidos, 45373
- Upper Valley Medical Center
-
Troy, Ohio, Estados Unidos, 45373
- Dayton Physicians LLC - Troy
-
Wadsworth, Ohio, Estados Unidos, 44281
- University Hospitals Sharon Health Center
-
Westerville, Ohio, Estados Unidos, 43081
- Saint Ann's Hospital
-
Westlake, Ohio, Estados Unidos, 44145
- UHHS-Westlake Medical Center
-
Zanesville, Ohio, Estados Unidos, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Estados Unidos, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Oregon
-
Bend, Oregon, Estados Unidos, 97701
- Saint Charles Health System
-
Clackamas, Oregon, Estados Unidos, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, Estados Unidos, 97015
- Providence Cancer Institute Clackamas Clinic
-
Coos Bay, Oregon, Estados Unidos, 97420
- Bay Area Hospital
-
Newberg, Oregon, Estados Unidos, 97132
- Providence Newberg Medical Center
-
Oregon City, Oregon, Estados Unidos, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, Estados Unidos, 97213
- Providence Portland Medical Center
-
Portland, Oregon, Estados Unidos, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Abington, Pennsylvania, Estados Unidos, 19001
- Jefferson Abington Hospital
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Estados Unidos, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Chadds Ford, Pennsylvania, Estados Unidos, 19317
- Christiana Care Health System-Concord Health Center
-
Ephrata, Pennsylvania, Estados Unidos, 17522
- Ephrata Cancer Center
-
Gettysburg, Pennsylvania, Estados Unidos, 17325
- Adams Cancer Center
-
Hanover, Pennsylvania, Estados Unidos, 17331
- WellSpan Medical Oncology and Hematology
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania/Abramson Cancer Center
-
West Reading, Pennsylvania, Estados Unidos, 19611
- Reading Hospital
-
York, Pennsylvania, Estados Unidos, 17403
- WellSpan Health-York Cancer Center
-
York, Pennsylvania, Estados Unidos, 17403
- WellSpan Health-York Hospital
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Boiling Springs, South Carolina, Estados Unidos, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Charleston, South Carolina, Estados Unidos, 29425
- Medical University of South Carolina
-
Easley, South Carolina, Estados Unidos, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Estados Unidos, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Estados Unidos, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, Estados Unidos, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health Greenville Memorial Hospital
-
Greenville, South Carolina, Estados Unidos, 29601
- Greenville Health System Cancer Institute-Andrews
-
Greer, South Carolina, Estados Unidos, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, Estados Unidos, 29672
- Prisma Health Cancer Institute - Seneca
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57105
- Avera Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37404
- Memorial Hospital
-
Hixson, Tennessee, Estados Unidos, 37343
- Pulmonary Medicine Center of Chattanooga-Hixson
-
Ooltewah, Tennessee, Estados Unidos, 37363
- Memorial GYN Plus
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- UT MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Huntsman Cancer Institute/University of Utah
-
South Jordan, Utah, Estados Unidos, 84009
- South Jordan Health Center
-
-
Virginia
-
Falls Church, Virginia, Estados Unidos, 22042
- Inova Fairfax Hospital
-
-
Washington
-
Aberdeen, Washington, Estados Unidos, 98520
- Providence Regional Cancer System-Aberdeen
-
Anacortes, Washington, Estados Unidos, 98221
- Cancer Care Center at Island Hospital
-
Bellevue, Washington, Estados Unidos, 98005
- Swedish Cancer Institute-Eastside Oncology Hematology
-
Bellingham, Washington, Estados Unidos, 98225
- PeaceHealth Saint Joseph Medical Center
-
Burien, Washington, Estados Unidos, 98166
- Saint Anne Hospital
-
Centralia, Washington, Estados Unidos, 98531
- Providence Regional Cancer System-Centralia
-
Edmonds, Washington, Estados Unidos, 98026
- Swedish Cancer Institute-Edmonds
-
Enumclaw, Washington, Estados Unidos, 98022
- Saint Elizabeth Hospital
-
Everett, Washington, Estados Unidos, 98201
- Providence Regional Cancer Partnership
-
Federal Way, Washington, Estados Unidos, 98003
- Saint Francis Hospital
-
Issaquah, Washington, Estados Unidos, 98029
- Swedish Cancer Institute-Issaquah
-
Lacey, Washington, Estados Unidos, 98503
- Providence Regional Cancer System-Lacey
-
Lakewood, Washington, Estados Unidos, 98499
- Saint Clare Hospital
-
Longview, Washington, Estados Unidos, 98632
- PeaceHealth Saint John Medical Center
-
Poulsbo, Washington, Estados Unidos, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, Estados Unidos, 98107
- Swedish Medical Center-Ballard Campus
-
Seattle, Washington, Estados Unidos, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Estados Unidos, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Estados Unidos, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Estados Unidos, 98104
- Minor and James Medical PLLC
-
Seattle, Washington, Estados Unidos, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Estados Unidos, 98133
- University of Washington Medical Center - Northwest
-
Seattle, Washington, Estados Unidos, 98133
- Women's Cancer Center of Seattle
-
Shelton, Washington, Estados Unidos, 98584
- Providence Regional Cancer System-Shelton
-
Silverdale, Washington, Estados Unidos, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane, Washington, Estados Unidos, 99218
- Evergreen Hematology and Oncology PS
-
Spokane, Washington, Estados Unidos, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane Valley, Washington, Estados Unidos, 99216
- MultiCare Deaconess Cancer and Blood Specialty Center - Valley
-
Tacoma, Washington, Estados Unidos, 98405
- Northwest Medical Specialties PLLC
-
Tacoma, Washington, Estados Unidos, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
Vancouver, Washington, Estados Unidos, 98664
- PeaceHealth Southwest Medical Center
-
Walla Walla, Washington, Estados Unidos, 99362
- Providence Saint Mary Regional Cancer Center
-
Yakima, Washington, Estados Unidos, 98902
- North Star Lodge Cancer Center at Yakima Valley Memorial Hospital
-
Yelm, Washington, Estados Unidos, 98597
- Providence Regional Cancer System-Yelm
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26505
- Monongalia Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
-
Wyoming
-
Cody, Wyoming, Estados Unidos, 82414
- Big Horn Basin Cancer Center
-
Cody, Wyoming, Estados Unidos, 82414
- Billings Clinic-Cody
-
Sheridan, Wyoming, Estados Unidos, 82801
- Welch Cancer Center
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Patients must have persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma of the cervix with documented disease progression (disease not amendable to curative therapy); NOTE: the following cervical tumors are not eligible: minimal deviation/adenoma malignum, gastric type adenocarcinoma, clear cell carcinoma and mesonephric carcinoma; histologic confirmation of the original primary tumor is required via the pathology report
-
All patents must have measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
-
Patients must have at least one "target" lesion" to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
-
Appropriate for study entry based on the following diagnostic workup:
-
History/physical examination within 28 days prior to registration
-
Imaging of target lesion(s) within 28 days prior to registration
-
Further protocol-specific assessments:
- Recovery from adverse effects of recent surgery, radiotherapy or chemotherapy
- Any other prior therapy directed at the malignant tumor including chemotherapy, biologic/targeted agents and immunologic agents must be discontinued at least three weeks prior to registration
- Investigation agents must be discontinued for at least 30 days prior to registration
- Any prior radiation therapy must be completed at least 4 weeks prior to registration
- At least 4 weeks must have elapsed since any major surgery prior to registration
-
-
Patients must have had one prior systemic chemotherapeutic regimen for management of persistent, recurrent or metastatic carcinoma of the cervix (e.g.; paclitaxel/cisplatin, paclitaxel/cisplatin/bevacizumab); chemotherapy administered concurrent with primary radiation (e.g.; weekly cisplatin) is not counted as a systemic chemotherapy regimen; adjuvant chemotherapy given following the completion of radiation therapy (or concurrent chemotherapy and radiation therapy) is not counted as a systemic chemotherapy regimen (e.g.; paclitaxel and carboplatin for up to 4 cycles); NOTE: patients who have received more than one prior regimen are NOT eligible
-
Performance status of 0 or 1
-
Absolute neutrophil count (ANC) >= 1,500/ul
-
Platelets >= 100,000/ul
-
Creatinine =< 1.5 x institutional upper limit of normal (ULN) or creatinine clearance (CrCl) >= 40 mL/min using Cockcroft-Gault formula
-
Bilirubin =< 1.5 x ULN
-
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
-
Normal thyroid function testing (thyroid stimulating hormone [TSH]) within 14 days prior to registration
-
The patient or a legally authorized representative must provide study-specific informed consent authorization permitting release of personal health information prior to study entry
Exclusion Criteria:
-
Patients who have had prior therapy with nivolumab or with an anti-PD-1, anti-PD-ligand (L)1, anti-PD-L2, anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune check point pathways
-
History of severe hypersensitivity reaction to any monoclonal antibody
-
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
-
Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure and unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Patients who are pregnant or nursing; women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; WOCBP should use an adequate method to avoid pregnancy for 23 weeks after the last dose of investigational drug; WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IV/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab; women must not be breastfeeding
- Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile or have undergone definitive radiation) do not require contraception
- Women of childbearing potential (WOCBP) is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy of bilateral oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12 month amenorrhea in a woman over 45 in the absence of other biological or physiological causes; in addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level greater than 40 mIU/mL
- WOCBP receiving nivolumab will be instructed to adhere to contraception for a period of 23 weeks after the last dose of investigational product
- Should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform the treating physician immediately
-
Patients with known brain metastases or leptomeningeal metastases are excluded unless the following conditions are met:
- Metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for at least 4 weeks after treatment is complete (must be confirmed within 28 days prior to the first dose of nivolumab administration)
- There must also be no requirement for immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration
-
Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- Patients should be excluded if they have a positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
-
Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded; these include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IRB), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded; patient with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible; patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible
- NOTE: patients are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger (precipitating event)
-
Patients should be excluded if they have a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration; inhaled or topical steroids and adrenal replacement doses =< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; patients are permitted to use topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption); physiologic replacement doses of systemic corticosteroids are permitted, even if =< 10 mg/day prednisone equivalents; a brief course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by contact allergen) is permitted
-
Patients who have had evidence of active or acute diverticulitis, intra-abdominal abscess, abdominal/pelvic fistula, gastrointestinal perforation, gastrointestinal (GI) obstruction and/or who require parenteral hydration and/or nutrition
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Treatment (nivolumab)
Patients receive nivolumab IV over approximately 60 minutes every 2 weeks for a maximum of 46 doses over 92 weeks in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective Tumor Response as Assessed by RECIST 1.1 Criteria
Prazo: The average of study treatment time was 3.8 months.
|
Proportion of participants with objective tumor response. Objective tumor response is defined as complete or partial tumor response assessed by RECIST 1.1. |
The average of study treatment time was 3.8 months.
|
|
Adverse Events (Grade 3 or Higher) During Treatment Period as Assessed by CTCAE Version 4
Prazo: Within 100 days of last protocol treatment
|
Number of participants with a maximum grade of 3 or higher during treatment period. Adverse events are graded and categorized using CTCAE v4.0. |
Within 100 days of last protocol treatment
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free Survival
Prazo: Time from study entry to time of progression or death, whichever occurs first, up to 5 years of follow-up.
|
Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first. Progression is assessed by RECIST 1.1. |
Time from study entry to time of progression or death, whichever occurs first, up to 5 years of follow-up.
|
|
Overall Survival
Prazo: Time from study entry to time of death or the date of last contact, up to 5 years of follow-up
|
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. |
Time from study entry to time of death or the date of last contact, up to 5 years of follow-up
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Tumor Expressions of PD-1 and PD-L1 in Tumor Infiltrating Lymphocytes and Cervical Cancer Cells
Prazo: Up to 5 years
|
Spearman's correlation coefficient will be used to explore the associations of tumor expressions of PD-L1, PD-1 and other interested biomarkers with tumor response. Cox proportional hazards (PH) model will be utilized to evaluate the associations of these tumor expressions with PFS and OS. These expressions may also be dichotomized into high versus low values (cut at the median). Log-rank tests will be used to assess the associations of these dichotomized tumor expressions with PFS and OS. The corresponding hazard rations will be estimated by Cox PH models. |
Up to 5 years
|
|
Immune Infiltration Related Biomarkers (i.e., CD4+, CD8+, FoxP3) in Tumor Specimens
Prazo: Up to 5 years
|
Immune infiltration related biomarkers (i.e., CD4+, CD8+, FoxP3) in tumor specimens will be associated with objective tumor response, PFS and OS in nivolumab-treated patients. |
Up to 5 years
|
|
Change in the Immune Response to HPV 16/18/31/35/45 E7 Antigen in Peripheral Blood Lymphocytes and Serum
Prazo: Baseline to up to 5 years
|
Wilcoxon signed rank test (for interval or ordinal data) or McNemar's test (for binary data) may be utilized to examine whether the study treatment will change immune response to HPV 16/18/31/35/45 E7 antigen in peripheral blood lymphocytes and serum by changes in the measures of pre- and post-treatment immune response to HPV 16/18/31/35/45 E7. |
Baseline to up to 5 years
|
|
Change in the CTC Count
Prazo: Baseline to up to 12 weeks
|
Change in the CTC count and whether the CTC count is associated with objective response, PFS and OS in nivolumab-treated patients will be evaluated. |
Baseline to up to 12 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Alessandro D Santin, NRG Oncology
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimado)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças uterinas
- Doenças Genitais Femininas
- Neoplasias Genitais Femininas
- Doenças do colo do útero
- Neoplasias uterinas
- Neoplasias do colo uterino
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Nivolumabe
Outros números de identificação do estudo
Outros números de identificação do estudo
- NCI-2014-02021
- U10CA180868 (Concessão/Contrato do NIH dos EUA)
- NCI-2014-02021 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- PNRG-GY002_A01PAMDREVW01
- NRG-GY002 (Outro identificador: CTEP)
- NRG-GY002
- NRG-GY002 (Outro identificador: NRG Oncology)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .